C4X Discovery’s Clive Dix and Bhavna Hunjan join Proactive’s Katie to talk about the significance of hitting its first milestone in a licensing deal with Sanofi for a new immunotherapy drug.
This is all part of a €414m partnership signed in April 2021, which sees the two companies collaborating on an oral interleukin 17A inhibitor.
Dix also updates on the progress of its drug licensed to Invidior, partnership discussions on two anti-inflammatory drugs plus a Malt-1 inhibitor and six new programmes in the pipeline.
